https://beta.curateqbio.com/news/ 2026-04-06T07:25:21+00:00 https://beta.curateqbio.com/press-release/curateq-biologics-announces-positive-phase-3-results-for-denosumab-biosimilar/ 2026-02-25T10:03:50+00:00 https://static.curateqbio.com/wp-content/uploads/2023/01/shutterstock_1971115256.png https://beta.curateqbio.com/press-release/curateq-biologics-receives-chmp-positive-opinion-for-dazublys-trastuzumab-biosimilar/ 2026-02-25T10:08:57+00:00 https://static.curateqbio.com/wp-content/uploads/2023/04/Screenshot-2022-11-15-at-15.02.06.jpg https://beta.curateqbio.com/press-release/curateq-biologics-completes-phase-1-study-for-denosumab-biosimilar/ 2026-02-25T10:12:36+00:00 https://static.curateqbio.com/wp-content/uploads/2022/01/3962487-scaled.jpg https://beta.curateqbio.com/press-release/curateq-biologics-receives-chmp-positive-opinion-for-pegfilgrastim-biosimilar/ 2026-02-25T10:14:14+00:00 https://static.curateqbio.com/wp-content/uploads/2022/01/blank-white-label-injection-bottle-glass-vial-with-syringe-scaled.jpg https://beta.curateqbio.com/press-release/curateq-biologics-receives-uk-mhra-approval-for-bevqolva-bevacizumab-biosimilar/ 2026-02-25T10:16:44+00:00 https://static.curateqbio.com/wp-content/uploads/2022/01/3956381-scaled.jpg https://beta.curateqbio.com/press-release/curateq-biologics-receives-chmp-positive-opinion-for-filgrastim-biosimilar/ 2026-02-25T10:19:23+00:00 https://static.curateqbio.com/wp-content/uploads/2022/01/blank-white-label-injection-bottle-glass-vial-with-syringe-scaled.jpg https://beta.curateqbio.com/press-release/curateq-biologics-receives-ema-gmp-certificate/ 2026-02-25T10:20:19+00:00 https://static.curateqbio.com/wp-content/uploads/2024/01/infrastructure-scaled.jpg https://beta.curateqbio.com/press-release/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar/ 2026-02-25T10:22:32+00:00 https://static.curateqbio.com/wp-content/uploads/2022/01/3966736-scaled.jpg https://beta.curateqbio.com/press-release/auro-peptides-completes-us-fda-inspection-with-zero-observations/ 2026-02-25T10:23:42+00:00 https://static.curateqbio.com/wp-content/uploads/2024/02/Auro-Peptides.jpg https://beta.curateqbio.com/press-release/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india/ 2026-02-25T10:24:52+00:00 https://static.curateqbio.com/wp-content/uploads/2024/01/infrastructure-scaled.jpg https://beta.curateqbio.com/press-release/curateq-biologics-enters-into-global-biologics-cdmo-space/ 2026-02-25T10:26:09+00:00 https://static.curateqbio.com/wp-content/uploads/2023/02/header-biosimilar-manufacturing.png https://beta.curateqbio.com/press-release/curateq-biologics-onboards-ustekinumab-biosimilar/ 2026-02-25T10:27:22+00:00 https://static.curateqbio.com/wp-content/uploads/2023/09/ustekinumab_biosimilar.png https://beta.curateqbio.com/press-release/curateq-biologics-announces-positive-phase-3-results-for-trastuzumab-biosimilar/ 2026-02-25T10:29:12+00:00 https://static.curateqbio.com/wp-content/uploads/2023/09/positive_phase-3.png https://beta.curateqbio.com/press-release/aurobindo-pharma-arm-curateq-expands-scope-of-biosimilars-distribution-pact-with-orion/ 2026-02-25T10:31:02+00:00 https://static.curateqbio.com/wp-content/uploads/2023/09/aurobindo_pharma_news.png https://beta.curateqbio.com/press-release/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag/ 2026-02-25T10:32:27+00:00 https://static.curateqbio.com/wp-content/uploads/2023/03/contact-building-shot.jpg https://beta.curateqbio.com/press-release/curateq-biologics-receives-ec-marketing-authorization-for-trastuzumab-biosimilar-dazublys/ 2026-04-06T07:25:21+00:00 https://static.curateqbio.com/wp-content/uploads/2024/01/infrastructure-scaled.jpg